At Equity.Guru, engaged as we are in market awareness programs for public companies, we often see competing entities that are more promotional than journalistic, banging out borderline insanity regarding…
Psychedelics
Brain trauma/CTE Lobe Sciences (LOBE.C) is working to develop effective psychedelic-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder with a focus on contact…
Core One Labs (COOL.C) announced their wholly-owned subsidiary, Akome Biotech, has begun the development of its patent-pending psychedelic drug formulation for the treatment of Alzheimer’s Disease. Akome’s “next-generation” psychedelic…
Novamind (NM.C) announced they are opening four new Cedar Psychiatric clinics, doubling the number of clinics in there network. The expanded capacity for the new clinics is intended to…
“Say something, goddammit! You are on television! You’re live to the whole world!” – The Truman Show After multiple attempts at writing a story on HAVN Life Sciences (HAVN.C)…
Last week Cybin (CYBN.NE) announced it was targetting alcoholism with its novel psychedelic compound CYB003. Another EG staffer wrote a piece last Monday outlining the details of the plan,…
Core One Labs (COOL.C) has completed the acquisition of Akome Biotech, a psychedelic-based pharmaceuticals company focused on providing effective and safe solutions to patients suffering from stroke and neurological…
PFN Program Tryp Therapeutics (TRYP.C) is a Kelowna-based psychedelics company looking to improve the lives of those with fibromyalgia, hyperphagia, and eating disorders. In the company’s young life so…
Mind Cure (MCUR.C), a leader in advanced proprietary technology for psychedelic therapy, has provided updates regarding its financial position, near-term revenue strategy, and a timeline for iSTRYM’s market launch….